FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522060219> ?p ?o ?g. }

• W2522060219 endingPage "419.e4" @default.
• W2522060219 startingPage "410" @default.
• W2522060219 abstract "Background Severe asthma in children is a heterogeneous disorder associated with variable responses to corticosteroid treatment. Criterion standards for corticosteroid responsiveness assessment in children are lacking. Objective This study sought to characterize systemic corticosteroid responses in children with severe asthma after treatment with intramuscular triamcinolone and to identify phenotypic and molecular predictors of an intramuscular triamcinolone response. Methods Asthma-related quality of life, exhaled nitric oxide, blood eosinophils, lung function, and inflammatory cytokine and chemokine mRNA gene expression in peripheral blood mononuclear cells were assessed in 56 children with severe asthma at baseline and 14 days after intramuscular triamcinolone injection. The Asthma Control Questionnaire was used to classify children with severe asthma into corticosteroid response groups. Results Three groups of children with severe asthma were identified: controlled severe asthma, children who achieved control after triamcinolone, and children who did not achieve control. At baseline, these groups were phenotypically similar. After triamcinolone, discordance between symptoms, lung function, exhaled nitric oxide, and blood eosinophils was noted. Clinical phenotypic predictors were of limited utility in predicting the triamcinolone response, whereas systemic mRNA expression of inflammatory cytokines and chemokines related to IL-2, IL-10, and TNF signaling pathways, namely, AIMP1, CCR2, IL10RB, and IL5, strongly differentiated children who failed to achieve control with triamcinolone administration. Conclusions Systemic corticosteroid responsiveness in children with severe asthma is heterogeneous. Alternative prediction models that include molecular endotypic as well as clinical phenotypic features are needed to identify which children derive the most clinical benefit from systemic corticosteroid step-up therapy given the potential side effects. Severe asthma in children is a heterogeneous disorder associated with variable responses to corticosteroid treatment. Criterion standards for corticosteroid responsiveness assessment in children are lacking. This study sought to characterize systemic corticosteroid responses in children with severe asthma after treatment with intramuscular triamcinolone and to identify phenotypic and molecular predictors of an intramuscular triamcinolone response. Asthma-related quality of life, exhaled nitric oxide, blood eosinophils, lung function, and inflammatory cytokine and chemokine mRNA gene expression in peripheral blood mononuclear cells were assessed in 56 children with severe asthma at baseline and 14 days after intramuscular triamcinolone injection. The Asthma Control Questionnaire was used to classify children with severe asthma into corticosteroid response groups. Three groups of children with severe asthma were identified: controlled severe asthma, children who achieved control after triamcinolone, and children who did not achieve control. At baseline, these groups were phenotypically similar. After triamcinolone, discordance between symptoms, lung function, exhaled nitric oxide, and blood eosinophils was noted. Clinical phenotypic predictors were of limited utility in predicting the triamcinolone response, whereas systemic mRNA expression of inflammatory cytokines and chemokines related to IL-2, IL-10, and TNF signaling pathways, namely, AIMP1, CCR2, IL10RB, and IL5, strongly differentiated children who failed to achieve control with triamcinolone administration. Systemic corticosteroid responsiveness in children with severe asthma is heterogeneous. Alternative prediction models that include molecular endotypic as well as clinical phenotypic features are needed to identify which children derive the most clinical benefit from systemic corticosteroid step-up therapy given the potential side effects." @default.
• W2522060219 created "2016-09-30" @default.
• W2522060219 creator A5019243806 @default.
• W2522060219 creator A5042721747 @default.
• W2522060219 creator A5045566760 @default.
• W2522060219 creator A5048989315 @default.
• W2522060219 creator A5073349266 @default.
• W2522060219 creator A5090039633 @default.
• W2522060219 date "2017-03-01" @default.
• W2522060219 modified "2023-10-03" @default.
• W2522060219 title "Systemic Corticosteroid Responses in Children with Severe Asthma: Phenotypic and Endotypic Features" @default.
• W2522060219 cites W1570938778 @default.
• W2522060219 cites W1598054520 @default.
• W2522060219 cites W1901763246 @default.
• W2522060219 cites W1964669406 @default.
• W2522060219 cites W1966718625 @default.
• W2522060219 cites W1972881815 @default.
• W2522060219 cites W1974262000 @default.
• W2522060219 cites W1974904073 @default.
• W2522060219 cites W1990155134 @default.
• W2522060219 cites W1991969116 @default.
• W2522060219 cites W1995548154 @default.
• W2522060219 cites W2002427641 @default.
• W2522060219 cites W2003292549 @default.
• W2522060219 cites W2009540187 @default.
• W2522060219 cites W2014278634 @default.
• W2522060219 cites W2024699476 @default.
• W2522060219 cites W2026921698 @default.
• W2522060219 cites W2027388164 @default.
• W2522060219 cites W2030003617 @default.
• W2522060219 cites W2039051609 @default.
• W2522060219 cites W2041716712 @default.
• W2522060219 cites W2043897018 @default.
• W2522060219 cites W2051954214 @default.
• W2522060219 cites W2053471558 @default.
• W2522060219 cites W2076569736 @default.
• W2522060219 cites W2084286208 @default.
• W2522060219 cites W2086167722 @default.
• W2522060219 cites W2098276532 @default.
• W2522060219 cites W2101809936 @default.
• W2522060219 cites W2107649025 @default.
• W2522060219 cites W2120402937 @default.
• W2522060219 cites W2121341602 @default.
• W2522060219 cites W2126809220 @default.
• W2522060219 cites W2127186884 @default.
• W2522060219 cites W2129497949 @default.
• W2522060219 cites W2131537076 @default.
• W2522060219 cites W2131939939 @default.
• W2522060219 cites W2136241314 @default.
• W2522060219 cites W2137472260 @default.
• W2522060219 cites W2138055599 @default.
• W2522060219 cites W2141343329 @default.
• W2522060219 cites W2147123233 @default.
• W2522060219 cites W2154638180 @default.
• W2522060219 cites W2155934004 @default.
• W2522060219 cites W2158613286 @default.
• W2522060219 cites W2159338097 @default.
• W2522060219 cites W2160302514 @default.
• W2522060219 cites W2162445996 @default.
• W2522060219 cites W2189291740 @default.
• W2522060219 cites W2312690251 @default.
• W2522060219 cites W2615778352 @default.
• W2522060219 cites W4235755338 @default.
• W2522060219 cites W4239218095 @default.
• W2522060219 doi "https://doi.org/10.1016/j.jaip.2016.08.001" @default.
• W2522060219 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5346343" @default.
• W2522060219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27665382" @default.
• W2522060219 hasPublicationYear "2017" @default.
• W2522060219 type Work @default.
• W2522060219 sameAs 2522060219 @default.
• W2522060219 citedByCount "18" @default.
• W2522060219 countsByYear W25220602192017 @default.
• W2522060219 countsByYear W25220602192018 @default.
• W2522060219 countsByYear W25220602192019 @default.
• W2522060219 countsByYear W25220602192020 @default.
• W2522060219 countsByYear W25220602192021 @default.
• W2522060219 countsByYear W25220602192022 @default.
• W2522060219 crossrefType "journal-article" @default.
• W2522060219 hasAuthorship W2522060219A5019243806 @default.
• W2522060219 hasAuthorship W2522060219A5042721747 @default.
• W2522060219 hasAuthorship W2522060219A5045566760 @default.
• W2522060219 hasAuthorship W2522060219A5048989315 @default.
• W2522060219 hasAuthorship W2522060219A5073349266 @default.
• W2522060219 hasAuthorship W2522060219A5090039633 @default.
• W2522060219 hasBestOaLocation W25220602192 @default.
• W2522060219 hasConcept C126322002 @default.
• W2522060219 hasConcept C13373296 @default.
• W2522060219 hasConcept C203014093 @default.
• W2522060219 hasConcept C2776042228 @default.
• W2522060219 hasConcept C2776804153 @default.
• W2522060219 hasConcept C2776914184 @default.
• W2522060219 hasConcept C2778903070 @default.
• W2522060219 hasConcept C2780333948 @default.
• W2522060219 hasConcept C2780401358 @default.
• W2522060219 hasConcept C2781142857 @default.
• W2522060219 hasConcept C71924100 @default.
• W2522060219 hasConceptScore W2522060219C126322002 @default.
• W2522060219 hasConceptScore W2522060219C13373296 @default.

• next